Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (131-140 of 195) with videos related to

Pageof 20
Sort By:
Transplantation and Cellular Therapy|August 3, 2025
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR AnalysisKalyan V Nadiminti, Kwang W Ahn, Jinalben Patel, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Frontiers in Immunology|December 22, 2018
Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor ImmunityBrian C Betts, Frederick L Locke, Elizabeth M Sagatys, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy|September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell TherapyAasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Pageof 20

Showing results (131-140 of 195) with videos related to

Sort By:
Pageof 20
Transplantation and Cellular Therapy|August 3, 2025
Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR AnalysisKalyan V Nadiminti, Kwang W Ahn, Jinalben Patel, et al.
Cancer Medicine|February 28, 2021
Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucelAasha I Hoogland, Reena V Jayani, Aaron Collier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.
Blood|June 2, 2020
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantationMatthew S Davids, Haesook T Kim, Caitlin Costello, et al.
Frontiers in Immunology|December 22, 2018
Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor ImmunityBrian C Betts, Frederick L Locke, Elizabeth M Sagatys, et al.
Blood Advances|October 14, 2021
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host diseaseAleksandr Lazaryan, Stephanie Lee, Mukta Arora, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Transplantation and Cellular Therapy|September 21, 2024
Prospective Assessment of Quality of Life and Patient-Reported Toxicities Over the First Year After Chimeric Antigen Receptor T-Cell TherapyAasha I Hoogland, Anna Barata, Xiaoyin Li, et al.
Journal of the American College of Cardiology|December 21, 2019
Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)Raza M Alvi, Matthew J Frigault, Michael G Fradley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Pageof 20